Novavax said on Tuesday that it has entered into a termination and settlement agreement with the UK Health Security Agency ...

Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Plus, options traders eye NVAX; CMI surges to fresh peak; and CE looks to extend losing streak.

A new study from the Centers for Disease Control and Prevention (CDC) reveals that fewer than one in six health workers ...

While it is too early to know how this season’s flu will play out, we do know that COVID-19 is still with us.’ ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Åsa ...

The government’s deal with Maryland-based Novavax requires the company to obtain regulatory approval for a vaccine using ingredients made at the Biologics Manufacturing Centre (BMC) in Montreal before ...

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Agios Pharma (AGIO – Research Report) today. The ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

The vaccine helps to prevent bacterial infections that can cause serious illness in older adults, such as pneumonia.

Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...

Northeastern University professors of pharmacy say the updated COVID-19 vaccines available for fall and winter of 2024 are a ...